Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

Patients with lymphoproliferative disorders such as chronic lymphocytic leukemia and mantle cell lymphoma (MCL) who are resistant to covalent Bruton tyrosine kinase inhibitors (cBTKis), especially if also venetoclax refractory, have an unmet therapeutic need. Pirtobrutinib, a noncovalent BTKi, achie...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Philip A., Tam, Constantine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Blood Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646821/
https://www.ncbi.nlm.nih.gov/pubmed/37156004
http://dx.doi.org/10.1182/blood.2023020240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646821/
https://www.ncbi.nlm.nih.gov/pubmed/37156004
http://dx.doi.org/10.1182/blood.2023020240

Ejemplares similares